Drug profile · INN
tarlatamab
IMDYLLTRA
tarlatamab (IMDYLLTRA) is a delta-like protein 3 binding agent.
Drug details — tarlatamab
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 0
- Programs
- 18
- Data quality
- 0.83
Quick answer
tarlatamab (IMDYLLTRA) is a delta-like protein 3 binding agent.
Key facts
Mechanism of action
Delta-like protein 3 binding agent
Primary target: Delta-like protein 3
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | unknown | — |
Recent coverage
EMA Backs Amgen's Tarlatamab as First-in-Class BiTE Therapy for Advanced Small Cell Lung Cancer
European regulators issue positive opinion for tarlatamab (Imdylltra), marking potential breakthrough in extensive-stage SCLC treatment options.
EMA Recommends First Bispecific T-Cell Engager for Relapsed Small Cell Lung Cancer
European regulators back Amgen's Imdylltra as breakthrough treatment for extensive-stage SCLC, marking first BiTE therapy approval in solid tumors.
FDA Approves Amgen's Bispecific Antibody for Metastatic Colorectal Cancer
The FDA has approved Amgen's bispecific antibody, providing a new treatment option for patients battling metastatic colorectal cancer.
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is tarlatamab?
tarlatamab (IMDYLLTRA) is a delta-like protein 3 binding agent.
What is the brand name for tarlatamab?
IMDYLLTRA is a marketed brand name for tarlatamab. Check FDA Drugs@FDA for the current US label holder and prescribing information.